Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Stratifying risk outcomes among adult COVID-19 inpatients with high flow oxygen: The R4 score

Autor: Reynaldo Lara-Medrano, J.F. Moreno-Hoyos, E.S. Velázquez-Ávila, G.M. Rhoades, C.A. Diaz-Garza, Victor M Sánchez-Nava, G.M. Aguirre-García, Guillermo Torre-Amione, M.T. Ramírez-Elizondo, Michel F. Martinez-Resendez, D. Ramonfaur, Fernando Castilleja-Leal

Publikováno v: Pulmonology

Background High flow oxygen therapy (HFO) is a widely used intervention for pulmonary complications. Amid the coronavirus infectious disease 2019 (COVID-19) pandemic, HFO became a popular alternative to conventional oxygen supplementation therapies.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ac01cfcf71d829b1ebfcdfba4fde8a5
https://doi.org/10.1016/j.pulmoe.2021.10.001

Survival Analysis of Multi-Omics Data Identifies Potential Prognostic Markers of Pancreatic Ductal Adenocarcinoma

Autor: Nitish Kumar Mishra, Siddesh Southekal, Chittibabu Guda

Publikováno v: Frontiers in Genetics, Vol 10 (2019)

Pancreatic ductal adenocarcinoma (PDAC) is the most common and among the deadliest of pancreatic cancers. Its 5-year survival is only ∼8%. Pancreatic cancers are a heterogeneous group of diseases, of which PDAC is particularly aggressive. Like many

Externí odkaz: https://doaj.org/article/bd7df8e38c34485cab4c6758fe427a9b

A multidisciplinary approach to optimizing care of patients treated with alpelisib

Autor: Rugo, Hope S., Lacouture, Mario E., Goncalves, Marcus D., Masharani, Umesh, Aapro, Matti S., O'Shaughnessy, Joyce A.

Publikováno v: Breast, Vol 61, Iss, Pp 156-167 (2022)
The Breast : Official Journal of the European Society of Mastology

Purpose The oral, α-specific phosphatidylinositol-3-kinase (PI3Kα) inhibitor alpelisib is the first PI3K inhibitor approved for the treatment of advanced breast cancer. As alpelisib is a relatively new therapeutic option, specific guidance and a mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ed100c67c3edaa21648be43be27980e
https://doi.org/10.1016/j.breast.2021.12.016

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers

Autor: Akdeniz, D., Barele, M. van, Heemskerk-Gerritsen, B.A.M., Steyerberg, E.W., Hauptmann, M., Beek, I. van de, Engelen, K. van, Wevers, M.R., Garcia, E.B.G., Ausems, M.G.E.M., Berger, L.P.V., Asperen, C.J. van, Adank, M.A., Collee, M.J., Stommel-Jenner, D.J., Jager, A., Schmidt, M.K., Hooning, M.J., HEBON Investigators

Publikováno v: HEBON Investigators 2021, ' Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers : A nationwide cohort study ', Breast, vol. 61, pp. 98-107 . https://doi.org/10.1016/j.breast.2021.12.007
The Breast : Official Journal of the European Society of Mastology
Breast, 61, 98-107. Churchill Livingstone
Breast, 61, 98-107
The Breast, 61, 98-107. CHURCHILL LIVINGSTONE
Breast, Vol 61, Iss, Pp 98-107 (2022)
Breast, 61, pp. 98-107

Aim BRCA1/2 mutation carriers with primary breast cancer (PBC) are at high risk of contralateral breast cancer (CBC). In a nationwide cohort, we investigated the effects of chemotherapeutic agents given for PBC on CBC risk separately in BRCA1 and BRC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ce7457047de708663f03e6da0e58460
https://doi.org/10.1016/j.breast.2021.12.007